Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population

The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis. (CAT) The main question it aims to answer is:

• Does extended prophylactic dose anticoagulant provide comparable efficacy and safety to therapeutic dosing after 6-month treatment of anticoagulant? The medical record data of participants who's already received for at least 6-month anticoagulant treatment upon regular medical care for CAT will be collected and analyzed about their recurrent thrombosis, anticoagulant related bleeding, and survival outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer-associated Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Adult patients aged ≥18 years with histopathological confirmed cancer, treated at Thammasat University Hospital and Panyananthaphikkhu Chonprathan Medical Center between January 2012 and December 2022, were eligible for inclusion.

Patients were initially screened using ICD-10 diagnostic codes C00-D009 for malignancy in conjunction with codes for venous thromboembolism (I82.-, other venous embolism and thrombosis; K55.0, mesenteric vein thrombosis; I82.0, hepatic vein thrombosis; K75.1, phlebitis of the portal vein; and I26.-, pulmonary embolism). Eligible patients required to have a radiologically confirmed diagnosis of cancer-associated thrombosis (CAT) and to have received anticoagulation therapy for at least six months. Clinical data were extracted from the Computerized Provider Order Entry (CPOE) system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Here's a polished version of your Inclusion and Exclusion Criteria section with grammar, spelling, and phrasing corrected for clarity and formal research style:

Inclusion criteria

Adult patients aged ≥18 years
Histopathologically confirmed cancer
Radiologically confirmed diagnosis of cancer-associated thrombosis (CAT)
Received anticoagulation therapy for at least six months Exclusion Criteria
Patients who do not meet the inclusion criteria

Treatment and study plan

Anticoagulant

Drug

warfarin at therapeutic level (INR 2-3), Low molecular weight heparin (LMWH) DOAC

Primary outcomes

Recurrent thrombosis

Time frame: After completing 6-month of treatment to the time that anticoagulant stop or recurrent thrombosis occurred through study completion, at the end of December 2025.

cumulative incidence of recurrent thrombosis

Secondary outcomes

Anticoagulant related bleeding

Time frame: After completing 6-month of treatment to the time that anticoagulant stop or bleeding occurred through study completion, at the end of December 2025.

cumulative incidence of bleeding
Overall survival

Time frame: The time from VTE diagnosis to last follow up or die through study completion, at the end of December 2025.

Overall survival

Sponsors and collaborators

Lead sponsor

Thammasat University

Other

Registry information

Official study title

Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis-A Ten Year Retrospective Study.

Important dates

Study start: 2012
Primary completion: 2025
Study completion: 2025
First posted: Feb 4, 2026
Registry last updated: Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed